Colorectal Carcinomas Containing Hypermethylated MLH1 Promoter and Wild-Type BRAF/KRAS Are Enriched for Targetable Kinase Fusions.
Adult
Aged
Aged, 80 and over
Biomarkers, Tumor
/ analysis
Colorectal Neoplasms
/ genetics
DNA Methylation
Female
Follow-Up Studies
Humans
Male
Microsatellite Instability
Middle Aged
MutL Protein Homolog 1
/ genetics
Mutation
Neoplasm Metastasis
Oncogene Proteins, Fusion
/ analysis
Prognosis
Promoter Regions, Genetic
Proto-Oncogene Proteins B-raf
/ genetics
Proto-Oncogene Proteins p21(ras)
/ genetics
Journal
Cancer research
ISSN: 1538-7445
Titre abrégé: Cancer Res
Pays: United States
ID NLM: 2984705R
Informations de publication
Date de publication:
15 03 2019
15 03 2019
Historique:
received:
03
10
2018
revised:
16
11
2018
accepted:
08
01
2019
pubmed:
16
1
2019
medline:
19
12
2019
entrez:
16
1
2019
Statut:
ppublish
Résumé
Kinase fusions are rare and poorly characterized in colorectal carcinoma, yet they present unique opportunities for targeted therapy. In this study, we characterized kinase fusions from patients with advanced colorectal carcinoma who had MSK-IMPACT testing of their tumors between January 2014 and June 2018. Patients were analyzed for the presence of fusions, microsatellite instability (MSI), and
Identifiants
pubmed: 30643016
pii: 0008-5472.CAN-18-3126
doi: 10.1158/0008-5472.CAN-18-3126
pmc: PMC6420871
mid: NIHMS1518804
doi:
Substances chimiques
Biomarkers, Tumor
0
KRAS protein, human
0
MLH1 protein, human
0
Oncogene Proteins, Fusion
0
BRAF protein, human
EC 2.7.11.1
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
MutL Protein Homolog 1
EC 3.6.1.3
Proto-Oncogene Proteins p21(ras)
EC 3.6.5.2
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1047-1053Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA226864
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA009207
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
©2019 American Association for Cancer Research.
Références
Ann Oncol. 2018 Jun 1;29(6):1394-1401
pubmed: 29538669
Mol Cell. 2014 Sep 18;55(6):904-915
pubmed: 25219500
J Natl Compr Canc Netw. 2017 Mar;15(3):370-398
pubmed: 28275037
Epigenomics. 2016 Mar;8(3):389-99
pubmed: 26673039
Mol Cancer Res. 2016 Mar;14(3):296-301
pubmed: 26660078
Am J Surg Pathol. 2017 Nov;41(11):1547-1551
pubmed: 28719467
N Engl J Med. 2018 Feb 22;378(8):731-739
pubmed: 29466156
JCO Precis Oncol. 2017;2017:
pubmed: 30211344
Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3314-22
pubmed: 18089725
Clin Cancer Res. 2016 Aug 1;22(15):3831-40
pubmed: 26933125
Nat Med. 2014 Dec;20(12):1479-84
pubmed: 25384085
Lancet Oncol. 2017 Sep;18(9):1182-1191
pubmed: 28734759
Am J Surg Pathol. 2016 Oct;40(10):1390-9
pubmed: 27438990
Science. 2017 Jul 28;357(6349):409-413
pubmed: 28596308
J Mol Diagn. 2015 May;17(3):251-64
pubmed: 25801821